IL114151A - Insulin analog formulations - Google Patents

Insulin analog formulations

Info

Publication number
IL114151A
IL114151A IL11415195A IL11415195A IL114151A IL 114151 A IL114151 A IL 114151A IL 11415195 A IL11415195 A IL 11415195A IL 11415195 A IL11415195 A IL 11415195A IL 114151 A IL114151 A IL 114151A
Authority
IL
Israel
Prior art keywords
insulin analog
analog formulations
formulations
insulin
analog
Prior art date
Application number
IL11415195A
Other languages
English (en)
Other versions
IL114151A0 (en
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22989969&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL114151(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL114151A0 publication Critical patent/IL114151A0/xx
Publication of IL114151A publication Critical patent/IL114151A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL11415195A 1994-06-16 1995-06-14 Insulin analog formulations IL114151A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/260,634 US5474978A (en) 1994-06-16 1994-06-16 Insulin analog formulations

Publications (2)

Publication Number Publication Date
IL114151A0 IL114151A0 (en) 1995-10-31
IL114151A true IL114151A (en) 2000-09-28

Family

ID=22989969

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11415195A IL114151A (en) 1994-06-16 1995-06-14 Insulin analog formulations

Country Status (38)

Country Link
US (1) US5474978A (de)
JP (2) JP3171541B2 (de)
KR (1) KR100382326B1 (de)
CN (1) CN1105576C (de)
AT (1) AT408720B (de)
BE (1) BE1009408A5 (de)
BR (1) BR9502795A (de)
CA (1) CA2151560C (de)
CH (2) CH689250A5 (de)
CO (1) CO4410203A1 (de)
CZ (1) CZ287484B6 (de)
DE (1) DE19521720B4 (de)
DK (1) DK173015B1 (de)
ES (1) ES2091727B1 (de)
FI (1) FI118207B (de)
FR (2) FR2721214B1 (de)
GB (1) GB2291427B (de)
GR (1) GR1003004B (de)
HU (1) HU227240B1 (de)
IE (1) IE68853B1 (de)
IL (1) IL114151A (de)
IT (1) IT1276723B1 (de)
LU (1) LU88626A1 (de)
MY (1) MY115631A (de)
NL (1) NL1000566C2 (de)
NO (1) NO322128B1 (de)
NZ (1) NZ272359A (de)
PE (1) PE19496A1 (de)
PL (1) PL181310B1 (de)
PT (1) PT101722B (de)
RO (1) RO113530B1 (de)
RS (1) RS49577B (de)
RU (1) RU2152399C2 (de)
SE (1) SE509052C2 (de)
SI (1) SI9500200A (de)
TW (1) TW421596B (de)
UA (1) UA26874C2 (de)
ZA (1) ZA954943B (de)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5498088A (en) * 1992-07-27 1996-03-12 Choate; John I. M. Keyboard arrangement to maximize typing speed and ease of transition from a qwerty keyboard
US5836705A (en) * 1992-07-27 1998-11-17 Choate; John I. M. Keyboard arrangement to maximize typing speed and data entry and to ease transition from a qwerty keyboard
US5352050A (en) * 1992-07-27 1994-10-04 Choate John I M Keyboard arrangement to maximize typing speed and ease of transition from a QWERTY keyboard
DK72793D0 (da) * 1993-06-21 1993-06-21 Novo Nordisk As Nyt produkt
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5547929A (en) * 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
US5693609A (en) * 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
AR002976A1 (es) * 1995-03-31 1998-05-27 Lilly Co Eli Formulaciones farmaceuticas parenterales de efecto prolongado de insulina; cristales de dichos analogos aplicables en dichas formulaciones yprocedimiento de las formulaciones mencionadas
WO1997002043A1 (en) * 1995-06-30 1997-01-23 Novo Nordisk A/S Prevention of a disease having the characteristics of diabetes
UA72427C2 (en) * 1996-06-20 2005-03-15 Novo Nordisk As Water-soluble insulin preparation containing mannite, method for manufacturing composition containing soluble insulin or crystalline insulin
UA49890C2 (uk) * 1996-06-20 2002-10-15 Ново Нордіск А/С Водна інсулінова композиція, парентеральна фармацевтична композиція та спосіб поліпшення хімічної стабільності інсулінової композиції
CO4750643A1 (es) * 1997-06-13 1999-03-31 Lilly Co Eli Formulacion estable de la insulina que contiene l-arginina y protamina
BR9813111A (pt) 1997-10-24 2000-08-15 Lilly Co Eli Composições de insulina insolúveis
CO4970787A1 (es) * 1997-12-23 2000-11-07 Lilly Co Eli Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea
EP1044016B1 (de) * 1998-01-09 2005-03-16 Novo Nordisk A/S Stabilisierte insulin-zubereitungen
BR9914568A (pt) * 1998-10-16 2001-07-03 Novo Nordisk As Formulação aquosa de insulina, preparação de insulina e método de tratamento de diabetes do tipo i ou do tipo ii
US6211144B1 (en) 1998-10-16 2001-04-03 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
ES2177323T3 (es) * 1998-10-16 2002-12-01 Novo Nordisk As Preparaciones de insulina concentradas estables para la administracionpor via pulmonar.
US6635617B1 (en) 1998-10-16 2003-10-21 Novo Nordisk A/S Insulin preparations for pulmonary delivery containing menthol
EP1131089B1 (de) * 1998-11-18 2004-02-18 Novo Nordisk A/S Stabile wässrige insulinzubereitungen ohne phenol und kresol
US6489292B1 (en) 1998-11-18 2002-12-03 Novo Nordisk A/S Stable aqueous insulin preparations without phenol and cresol
US20040214747A1 (en) * 1999-01-06 2004-10-28 Dimarchi Richard Dennis Method for administering monomeric insulin
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
US6734162B2 (en) 2000-01-24 2004-05-11 Minimed Inc. Mixed buffer system for stabilizing polypeptide formulations
US7227033B2 (en) 2002-01-09 2007-06-05 Emisphere Technologies, Inc. Polymorphs of sodium 4-[(4-chloro-2-hydroxybenzoyl) amino] butanoate
AU8436401A (en) * 2000-07-31 2002-02-13 Univ Bar Ilan Methods and pharmaceutical compositions for healing wounds
US20040037828A1 (en) 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
DE10114178A1 (de) * 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
US6737401B2 (en) 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
RU2202365C2 (ru) * 2001-07-20 2003-04-20 Институт биоорганической химии им. М.М.Шемякина и Ю.А.Овчинникова РАН Способ приготовления быстродействующего раствора инсулина для инъекций
US20030211976A1 (en) * 2002-03-07 2003-11-13 Andreasen Kasper Huus Polyamino acid-based particle insulin formulation
US20040005999A1 (en) * 2002-03-07 2004-01-08 Andreasen Kasper Huus Polyamino acid-based particle insulin preparation
DE10227232A1 (de) * 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
US20060258561A1 (en) * 2003-03-13 2006-11-16 Novo Nordisk A/S Novel NPH insulin preparations
EP1633876B1 (de) 2003-06-17 2008-08-20 SemBioSys Genetics Inc. Verfahren zur insulinproduktion in pflanzen
US20060241019A1 (en) * 2003-07-25 2006-10-26 Bridon Dominique P Long lasting insulin derivatives and methods thereof
US7658721B2 (en) * 2004-01-16 2010-02-09 Biodel Inc. Sublingual drug delivery device
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
US20080085298A1 (en) * 2004-03-12 2008-04-10 Biodel, Inc. Rapid Mucosal Gel or Film Insulin Compositions
US20080096800A1 (en) * 2004-03-12 2008-04-24 Biodel, Inc. Rapid mucosal gel or film insulin compositions
US8636996B2 (en) 2004-05-06 2014-01-28 Emisphere Technologies, Inc Crystalline polymorphic forms of monosodium N-[-8-(2-hydroxybenzoyl)amino]caprylate
NZ551241A (en) * 2004-05-14 2010-08-27 Emisphere Tech Inc Aryl ketone compounds and compositions for delivering active agents
US20080044481A1 (en) * 2004-05-27 2008-02-21 Mordechai Harel Microparticles for Oral Delivery
PT1773878E (pt) 2004-07-19 2015-06-05 Biocon Ltd Conjugados de insulina-oligómero, formulaçôes e usos dos mesmos
EP2248531A1 (de) 2004-08-03 2010-11-10 Emisphere Technologies, Inc. Antidiabetische orale Insulinbiguanidkombination
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
US20060078623A1 (en) * 2004-08-13 2006-04-13 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
EP2926828B1 (de) * 2004-10-05 2019-12-11 Novo Nordisk A/S Pharmazeutische formulierung
US8263551B2 (en) 2004-11-22 2012-09-11 Novo Nordisk A/S Soluble, stable insulin-containing formulations with a protamine salt
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
WO2006093222A1 (ja) * 2005-03-02 2006-09-08 Ajinomoto Co., Inc. インスリンの多量体形成阻害剤
EP2452691A3 (de) 2005-08-29 2012-09-05 HealOr Ltd. Verfahren und Zusammensetzungen zur Vorbeugung von diabetischer und alternder Haut
JP2009508875A (ja) 2005-09-19 2009-03-05 エミスフェアー・テクノロジーズ・インク Ｎ−（５−クロロサリチロイル）−８−アミノカプリル酸二ナトリウム塩の結晶形
US8084420B2 (en) 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
US7713929B2 (en) * 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
EP1991575A1 (de) * 2006-02-21 2008-11-19 Novo Nordisk A/S Einkettige insulinanaloga und pharmazeutische formulierungen daraus
JP2009533471A (ja) 2006-04-12 2009-09-17 バイオデル， インコーポレイテッド 即効型および長時間作用型組合せインスリン製剤
WO2007121318A2 (en) 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin
ES2554773T3 (es) 2006-10-04 2015-12-23 Case Western Reserve University Insulina y análogos de la insulina resistentes a la fibrilación
WO2008112706A1 (en) 2007-03-13 2008-09-18 Nutrition 21, Inc. Methods and compositions for the sustained release of chromium
EP2136624A4 (de) * 2007-03-21 2011-11-30 Emisphere Tech Inc Abgabemittel für allyloxy- und alkyloxybenzoesäure
WO2008132229A2 (en) * 2007-04-30 2008-11-06 Novo Nordisk A/S Highly concentrated insulin solutions and compositions
WO2009002867A2 (en) 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
NZ585135A (en) 2007-10-16 2012-08-31 Biocon Ltd An orally administerable solid pharmaceutical composition comprising in-105 and a process thereof
PL2215047T3 (pl) 2007-11-02 2014-05-30 Emisphere Tech Inc Sposób leczenia niedoborów witaminy b12
MY158627A (en) 2008-07-31 2016-10-31 Univ Case Western Reserve Halogen-stabilized insulin
CN102209541B (zh) 2008-09-08 2016-05-18 小利兰·斯坦福大学托管委员会 醛脱氢酶活性调节剂和其使用方法
LT2349324T (lt) 2008-10-17 2017-12-27 Sanofi-Aventis Deutschland Gmbh Insulino ir glp-1 agonisto derinys
CN102202669A (zh) 2008-10-28 2011-09-28 利兰·斯坦福青年大学托管委员会 醛脱氢酶调节剂及其使用方法
SG193837A1 (en) 2009-01-28 2013-10-30 Smartcells Inc Conjugate based systems for controlled drug delivery
EP2391217A4 (de) 2009-01-28 2015-05-20 Smartcells Inc Synthetische konjugate und ihre verwendung
CA2750074A1 (en) 2009-02-12 2010-08-19 Proyecto De Biomedicina Cima, S.L. Use of cardiotrophin-1 for the treatment of metabolic diseases
US9060927B2 (en) 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
EP2408808A4 (de) 2009-03-20 2015-05-06 Smartcells Inc Terminal-funktionalisierte konjugate und ihre verwendung
CN102711804B (zh) 2009-11-13 2015-09-16 赛诺菲-安万特德国有限公司 包含glp-1激动剂和甲硫氨酸的药物组合物
JP5832439B2 (ja) 2009-11-13 2015-12-16 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｇｌｐ−１アゴニスト、インスリン及びメチオニンを含む薬学的組成物
AU2011204425A1 (en) 2010-01-11 2012-08-02 Healor Ltd. Method for treatment of inflammatory disease and disorder
AR080292A1 (es) * 2010-02-24 2012-03-28 Emisphere Tech Inc Metodo para normalizar en forma rapida los niveles de vitamina b12 en un paciente que tiene deficiencia de vitamina b12 y un nivel promedio de vitamina b12 por debajo de 350 pg/ml
CN103179978A (zh) 2010-08-30 2013-06-26 赛诺菲-安万特德国有限公司 Ave0010用于制造供治疗2型糖尿病用的药物的用途
CN107759771A (zh) 2010-09-30 2018-03-06 索尔维公司 天然来源的环氧氯丙烷的衍生物
WO2012115641A1 (en) 2011-02-23 2012-08-30 Elona Biotechnologies Lis-pro proinsulin compositions and methods of producing lis-pro insulin analogs therefrom
EP4070801A1 (de) 2011-03-01 2022-10-12 Nutrition 21, LLC Zusammensetzungen aus insulin und chrom zur behandlung und vorbeugung von diabetes, hypoglykämie und verwandten erkrankungen
US10457659B2 (en) 2011-04-29 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
WO2013030160A1 (en) 2011-08-29 2013-03-07 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
CN104010652A (zh) 2011-10-27 2014-08-27 卡斯西部储备大学 超浓缩的速效胰岛素类似物制剂
US10159735B2 (en) * 2012-06-26 2018-12-25 The Curators Of The University Of Missouri Photocleavable drug conjugates
DK2877200T3 (da) 2012-07-17 2019-08-12 Univ Case Western Reserve O-bundne carbonhydratmodificerede insulinanaloger
EP2919804B1 (de) 2012-11-13 2018-01-31 Adocia Schnell wirkende insulinformulierung mit einer anionischen substituierten verbindung
EP2925345B1 (de) 2012-12-03 2018-09-05 Merck Sharp & Dohme Corp. Methode zur herstellung von o-glycosyliertem carboxyterminus-peptid (ctp)-basiertem insulin und insulinanaloga
US9707275B2 (en) 2012-12-19 2017-07-18 Wockhardt Limited Stable aqueous composition comprising human insulin or an analogue or derivative thereof
JP2016505601A (ja) 2012-12-26 2016-02-25 ウォックハート リミテッド 医薬組成物
CN105358531B (zh) 2013-03-14 2017-11-14 利兰-斯坦福大学初级学院的董事会 线粒体醛脱氢酶‑2调节剂和其使用方法
AR098168A1 (es) 2013-10-25 2016-05-04 Sanofi Sa Formulación estable de insulina glulisina
EP3185887B1 (de) 2014-08-26 2021-03-10 Merck Sharp & Dohme Corp. Verfahren zur herstellung von kristallinem insulin oder insulin-analog-zusammensetzungen
MA41138B1 (fr) 2014-12-12 2023-07-31 Sanofi Aventis Deutschland Formulation à rapport fixe d'insuline glargine/lixisenatide
AR102869A1 (es) 2014-12-16 2017-03-29 Lilly Co Eli Composiciones de insulina de rápida acción
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
JO3749B1 (ar) 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
MX2018009748A (es) 2016-02-11 2019-02-07 Nutrition 21 Llc Composiciones que contienen cromo para mejorar la salud y el estado físico.
EA201992351A1 (ru) 2017-06-01 2020-03-26 Эли Лилли Энд Компани Быстродействующие композиции инсулина
WO2019125878A1 (en) 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Conjugate based systems for controlled insulin delivery
US11413352B2 (en) 2017-12-18 2022-08-16 Merck, Sharp & Dohme LLC Conjugate based systems for controlled insulin delivery
BR112022007593A2 (pt) 2019-10-25 2022-08-23 Cercacor Lab Inc Compostos indicadores, dispositivos que compreendem compostos indicadores e métodos de fabricação e uso dos mesmos
BR112022019687A2 (pt) 2020-03-31 2022-12-20 Protomer Tech Inc Conjugados para responsividade seletiva a dióis vicinais
MX2023005935A (es) 2020-11-19 2023-05-29 Protomer Tech Inc Compuestos aromaticos que contienen boro y analogos de insulina.
IL317049A (en) 2022-05-18 2025-01-01 Protomer Tech Inc Aromatic boron-containing compounds and related insulin analogs

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3060093A (en) * 1957-07-18 1962-10-23 Nordisk Insulinlab Slowly acting insulin preparation in crystalline form and method of preparation
DE2933946A1 (de) * 1979-08-22 1981-03-12 Hoechst Ag, 6000 Frankfurt Insulinkristallsuspension und verfahren zu ihrer herstellung.
FI78616C (fi) * 1982-02-05 1989-09-11 Novo Industri As Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
US4608634A (en) * 1982-02-22 1986-08-26 Texas Instruments Incorporated Microcomputer with offset in store-accumulator operations
DK347086D0 (da) * 1986-07-21 1986-07-21 Novo Industri As Novel peptides
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DE3717370A1 (de) * 1987-05-22 1988-12-01 Hoechst Ag Mischkristalle aus insulin und insulinderivaten, verfahren zur herstellung dieser mischkristalle, diese mischkristalle enthaltende pharmazeutische mittel und ihre verwendung zur behandlung von diabetes mellitus
KR900701842A (ko) * 1988-07-20 1990-12-04 헨리 브뢰늄 인간 인슐린 동족체와 그를 포함하는 제제
KR910700262A (ko) * 1988-12-23 1991-03-14 안네 제케르 사람 인슐린 유사체
NZ232375A (en) * 1989-02-09 1992-04-28 Lilly Co Eli Insulin analogues modified at b29
WO1995000550A1 (en) * 1993-06-21 1995-01-05 Novo Nordisk A/S Aspb28 insulin crystals
EP0792290B1 (de) * 1993-09-17 2001-08-29 Novo Nordisk A/S Acyliertes insulin
US5504188A (en) * 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5597893A (en) * 1994-10-31 1997-01-28 Eli Lilly And Company Preparation of stable insulin analog crystals
AR002976A1 (es) * 1995-03-31 1998-05-27 Lilly Co Eli Formulaciones farmaceuticas parenterales de efecto prolongado de insulina; cristales de dichos analogos aplicables en dichas formulaciones yprocedimiento de las formulaciones mencionadas

Also Published As

Publication number Publication date
SI9500200A (en) 1996-02-29
UA26874C2 (uk) 1999-12-29
PL181310B1 (pl) 2001-07-31
SE9502167D0 (sv) 1995-06-14
TW421596B (en) 2001-02-11
SE9502167L (sv) 1995-12-17
CZ287484B6 (en) 2000-12-13
NO952357L (no) 1995-12-18
PT101722A (pt) 1995-12-29
JPH083067A (ja) 1996-01-09
HU227240B1 (en) 2010-12-28
FR2721214B1 (fr) 1997-09-26
US5474978A (en) 1995-12-12
KR100382326B1 (ko) 2003-07-07
PT101722B (pt) 1997-02-28
CA2151560A1 (en) 1995-12-17
CZ154295A3 (en) 1996-02-14
ATA101695A (de) 2001-07-15
NZ272359A (en) 1996-10-28
NO322128B1 (no) 2006-08-21
CH689250A5 (de) 1999-01-15
ZA954943B (en) 1997-09-14
PL309098A1 (en) 1995-12-27
AU694501B2 (en) 1998-07-23
LU88626A1 (fr) 1996-02-01
ES2091727A1 (es) 1996-11-01
RU2152399C2 (ru) 2000-07-10
FI952931A0 (fi) 1995-06-14
ITMI951278A0 (it) 1995-06-14
HK1015138A1 (en) 1999-10-08
KR960000924A (ko) 1996-01-25
FR2741078B1 (fr) 1998-08-07
NL1000566A1 (nl) 1995-12-18
BE1009408A5 (fr) 1997-03-04
GB9512038D0 (en) 1995-08-09
FI952931L (fi) 1995-12-17
AU2168095A (en) 1996-01-04
ITMI951278A1 (it) 1996-12-14
SE509052C2 (sv) 1998-11-30
GR950100229A (en) 1996-02-29
PE19496A1 (es) 1996-06-01
DE19521720B4 (de) 2009-09-03
DK173015B1 (da) 1999-11-15
RU95110109A (ru) 1997-05-10
GB2291427B (en) 1998-09-16
JP3171541B2 (ja) 2001-05-28
CN1122248A (zh) 1996-05-15
IE68853B1 (en) 1996-07-24
AT408720B (de) 2002-02-25
RO113530B1 (ro) 1998-08-28
IL114151A0 (en) 1995-10-31
FR2721214A1 (fr) 1995-12-22
CN1105576C (zh) 2003-04-16
YU39695A (sh) 1997-08-22
MY115631A (en) 2003-08-30
DK67795A (da) 1995-12-17
ES2091727B1 (es) 1998-02-01
GB2291427A (en) 1996-01-24
IT1276723B1 (it) 1997-11-03
FI118207B (fi) 2007-08-31
HU9501716D0 (en) 1995-08-28
CO4410203A1 (es) 1997-01-09
NL1000566C2 (nl) 1996-12-03
NO952357D0 (no) 1995-06-14
BR9502795A (pt) 1996-03-12
FR2741078A1 (fr) 1997-05-16
IE950436A1 (en) 1995-12-27
CA2151560C (en) 2000-05-09
HUT73186A (en) 1996-06-28
DE19521720A1 (de) 1995-12-21
JP2001199899A (ja) 2001-07-24
GR1003004B (el) 1998-11-05
CH689935A5 (de) 2000-02-15
RS49577B (sr) 2007-04-10

Similar Documents

Publication Publication Date Title
GB2291427B (en) Insulin analog formulations
GB2290294B (en) Monomeric insulin analog formulations
HUP9801700A3 (en) Monomeric insulin analog formulations
AP9500733A0 (en) Pharmaceutical formulations
IL133348A0 (en) Stable insulin formulations
GB9404248D0 (en) Pharmaceutical formulations
AU731636C (en) Insulin analog formulations
AU694501C (en) Insulin analog formulations
EG26644A (en) Preparations of monoclonal insulin analogs
GB2327424B (en) Monomeric insulin analog formulations
HK1015138B (en) Insulin analog formulations
GB9413542D0 (en) Pharmaceutical formulations
AU2168295A (en) Monomeric insulin analog formulations
AU738101C (en) Monomeric insulin analog formulations
GB9409464D0 (en) Formulations
GB9408419D0 (en) Formulations
GB9406050D0 (en) Formulations
GB9401738D0 (en) Pharmaceutical formulations
GB9426113D0 (en) Pharmaceutical formulations
GB9417953D0 (en) Pharmaceutical formulations
GB9414216D0 (en) Pharmaceutical formulations
GB9408162D0 (en) Pharmaceutical formulations
GB9408164D0 (en) Pharmaceutical formulations
GB9408163D0 (en) Pharmaceutical formulations
GB9408151D0 (en) Pharmaceutical formulations

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired